This report examines the security posture of the pharmaceutical industry while delivering unique insights into external attack surface exposures and security issues that pharmaceutical companies are currently experiencing.
Read this to learn about:
- Most commonly exposed services in pharmaceutical companies’ external attack surface
- The most prevalent critical security issues discovered
- How to reduce unknown exposures and IT security risks
The data in this report was derived from Reposify’s External Attack Surface Management platform during March 2021. The report presents information about exposure of services and cybersecurity risks, which are prevalent among leading pharmaceutical companies and their 600+ subsidiaries worldwide.